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Abstract
Aerobic glycolysis and mitochondrial dysfunction are common features of aggressive cancer growth. We observed
promoter methylation and loss of expression in neurofilament heavy polypeptide (NEFH) in a significant proportion of
primary esophageal squamous cell carcinoma (ESCC) samples that were of a high tumor grade and advanced stage. RNA
interference-mediated knockdown of NEFH accelerated ESCC cell growth in culture and increased tumorigenicity in vivo,
whereas forced expression of NEFH significantly inhibited cell growth and colony formation. Loss of NEFH caused up-
regulation of pyruvate kinase-M2 type and down-regulation of pyruvate dehydrogenase, via activation of the Akt/b-catenin
pathway, resulting in enhanced aerobic glycolysis and mitochondrial dysfunction. The acceleration of glycolysis and
mitochondrial dysfunction in NEFH-knockdown cells was suppressed in the absence of b-catenin expression, and was
decreased by the treatment of 2-Deoxyglucose, a glycolytic inhibitor, or API-2, an Akt inhibitor. Loss of NEFH activates the
Akt/b-catenin pathway and increases glycolysis and mitochondrial dysfunction. Cancer cells with methylated NEFH can be
targeted for destruction with specific inhibitors of deregulated downstream pathways.
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Introduction
Esophageal squamous cell carcinoma (ESCC) is the eighth most
common type of caner, accounting for more than 90% cases of
esophageal cancer worldwide [1,2]. Most patients with ESCC are
diagnosed at an advanced stage, and metastasis to the regional
lymph nodes occurs frequently [3]. The development of ESCC is
associated with the accumulation of multiple genetic/epigenetic
alterations, including the activation of oncogenes and/or the
inactivation of tumor suppressor genes. Amplification and over-
expression of cyclin D1 [4], alterations in the p53 and p16
pathways [5,6], and mutations of p53 [7–9] and retinoblastoma
[10] are involved in development of ESCC. In addition,
hypermethylation of gene promoters and the corresponding loss
of gene expression are now recognized as a hallmark of human
cancer [11]. Most of the epigenetically silenced genes identified
possess tumor suppressive activity [11]. Promoter methylation of
MGMT [12] and RASSF1 [13] are involved in development of
ESCC. We have focused on the discovery of additional tumor
suppressor genes in ESCC inactivated by promoter methylation
[14].
b-catenin is a multifunctional protein involved in cell-cell
adhesion and signal transduction. In the Wnt signaling pathway, it
regulates cellular differentiation and proliferation. APC protein
targets b-catenin for destruction by interaction with b-catenin
[15], which requires phosphorylation of b-catenin by Gsk3b on 3
serines and one threonine residue, all of which are encoded in
exon 3 of the b-catenin gene [15,16]. Deletion of the NH2
terminus or mutation of one or more of the exon 3 inhibits the
ubiquitin-mediated degradation of b-catenin, increasing its
availability as a transcriptional activator. In colorectal cancers
[17] and several other tumors [18,19], loss of control of
intracellular b-catenin levels through mutation to either b-catenin
or APC result in stabilization of b-catenin and accumulation of the
protein in the cytoplasm. The increased concentration of b-catenin
in the cytoplasm favors its binding to the T-cell factor (TCF) family
of DNA-binding proteins [17], and it subsequently translocates to
the nucleus where it induces transcription of specific genes which
are involved in oncogenic transformation [20–30]. In the
development of esophageal cancer, dysfunction of Wnt/b-catenin
signaling has been implicated [26], however, in contrast to
colorectal cancer, mutation in adenomatous polyposis coli (APC)
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Increased expression and nuclear localization of b-catenin protein
are reported in ESCC [19,27,31–33], suggesting that the
accumulation of b-catenin in ESCC development does not result
from the genetic alterations of either the b-catenin or the APC
gene. Further mechanisms for nuclear and cytoplasmic b-catenin
accumulation are likely to exist in esophageal carcinogenesis.
The neurofilament heavy polypeptide (NEFH, 200 kD) gene
resides at chromosomal band 22q12.2 and was proposed as a
DNA marker for presymptomatic diagnosis in neurofibromatosis
type 2 (NF2) families [34,35]. The NEFH encoding neurofilament
heavy chain is one of the major components of the neuronal
cytoskeleton neurofilaments [36]. The role of NEFH has been
studied extensively in motor neurons that require a high level of
mitochondrial activity and harbor increased neurofilament content
compared to other neuronal groups [37]. Recently, an interaction
between neurofilaments and brain mitochondria was found to be
mediated by NEFH, and the binding was dependent on the
potential of the mitochondrial membranes [38]. Interestingly, both
NEFH and b-catenin are constituent proteins in the postsynaptic
density (PSD) in the mammalian central nervous system [39],
suggesting a cooperative function of NEFH and b-catenin in the
PSD.
Loss or down-regulation of NEFH has been mostly reported in
human autonomic nerve tumors or central neurocytomas [40–43].
In addition, absent or diminished NEFH expression in human
prostate cancer [44], clear-cell epithelioid tumor [45], and small
cell lung carcinoma [46] has been observed. Interestingly, over-
expression of NEFH disrupted normal cell structure and function,
and induced cell death [47]. Fibroblasts cells expressing high
amounts of NEFH were strongly misshapen, multinucleated, and
had many inclusions, typical changes seen in neuropathies [47].
These results suggest that NEFH is needed for maintaining normal
cell integrity and diminished NEFH levels are seen in common
cancers. However, precise function of NEFH in the human cancer
development remains to be investigated.
Here, we report NEFH as a novel tumor suppressor in ESCC.
Its expression is down-regulated by hypermethylation of the CpG
island in the promoter, and loss of NEFH increases glycolysis and
mitochondrial dysfunction through activation of the Akt/b-catenin
pathway. Epigenetic silencing of the NEFH gene in ESCC seems
to be responsible for increased b-catenin expression, leading to
activation of b-catenin/TCF-dependent transcription and key
downstream effectors, leading to ESCC progression.
Results
NEFH Promoter Is Methylated and Its Expression Is
Down-Regulated in ESCC
After identifying NEFH as a candidate methylated gene in
ESCC [14], we treated gDNA with bisulfite and re-sequenced the
NEFH promoter in 12 ESCC cell lines and 20 pairs of primary
ESCC (PT) with their corresponding normal esophageal tissues
(PN). All 12 ESCC cell lines tested and 65% (13/20) of PT
harbored NEFH promoter methylation, whereas no methylation
was found in paired normal samples (PN) (0%) and two non-
tumorigenic cell lines, HEK293 (Fig. S1). Methylation of the
NEFH promoter was further confirmed by conventional methyl-
ation-specific PCR (MSP) in three randomly selected pairs of
normal and tumor tissue samples. PCR-amplification with
methylation-specific primers was clearly seen only in PT whereas
amplification of non-methylated-DNA was seen only in PN,
consistent with the results of bisulfite-sequencing (Fig. 1a, left).
MSP analysis in primary ESCC tissues from five more patients
demonstrated NEFH promoter methylation in 3 cases while the
remaining two did not harbor methylation (Fig. 1a, right).
To quantify promoter methylation, real-time TaqMan-MSP
analysis was performed with a probe targeted to the CpG island of
NEFH. Forty-nine cases of primary ESCC and 15 normal
esophageal epithelial tissues from non-cancer patients (NN) were
included to compare methylation levels between cancer and non-
cancer patients. The distribution of methylation values in each
group of samples is shown in Figure 1b. The overall TaqMan
methylation value (TaqMeth V) detected in primary ESCC
(42.84668.13, mean 6 SD) was significantly higher than that in
normal tissues (0.0861.63, mean 6 SD) (P,0.001) (Fig. 1c).
Testing methylation of NEFH resulted in a highly discriminative
receiver–operator characteristic (ROC) curve profile, clearly
distinguishing ESCC from PN (Fig. 1d). The optimal cut-off
(value, 0.985) was calculated from the ROC analysis in order to
maximize sensitivity and specificity. No NN nor PN samples
exhibited a value over 0.985, yielding 100% specificity, while
85.5% (59/69) of primary ESCC tissues displayed NEFH
promoter methylation (P,0.001, ESCC vs. PN, Fisher’s exact test).
No correlation between clinical features and NEFH methylation
was found.
If functionally relevant, promoter methylation should correlate
with decreased expression or silencing of the gene. To examine the
transcriptional levels of NEFH, RT-PCR was performed using
primers specific for NEFH cDNA. NEFH expression was hardly
detectable in most of the ESCC cell lines except for KYSE30
(Fig. 1e, left). Moreover, NEFH expression was reactivated by 5-
Aza-dC in all ESCC cell lines, and the reactivation was stronger in
TE5, KYSE140, KYSE150, and KYSE520 but decreased or
minimally different in TE3 or KYSE410 when both 5-Aza-dC and
300 nM TSA were used (Fig. 1f and data not shown). Although
NEFH was expressed in KYSE30 at baseline, it was further
increased by 5-Aza-dC (Fig. 1e, middle), indicating that its
expression was at least partially suppressed by methylation. These
results suggest that promoter hypermethylation of NEFH is one of
the causal factors of loss of NEFH expression.
We then performed RT-PCR and real time RT-PCR in cDNA
prepared from tumor and normal tissues, and found that NEFH
was significantly down-regulated in ESCC (Fig. 1e, right and
Fig. 1g). To investigate protein expression of NEFH, we performed
immunohistochemical (IHC) staining using ESCC tissue arrays.
Among 26 pairs of ESCC (PT) with matched normal adjacent
tissues (PN) analyzed, decreased NEFH expression was observed in
10 cases (38.5%) (Table S1 and S2). NEFH expression was
detected in 24 out of 26 cases (92.3%) of non-malignant
esophageal tissues (normal, inflammation and hyperplasia),
whereas absent or faint expression of NEFH was observed in 35
out of 47 cases (74.5%) of neoplastic tissues (Table 1 and Table
S3). When compared to normal esophagus tissue, the negative
expression of NEFH in adenocarcinoma (75%, 15/20) (P,0.001),
squamous cell carcinoma (66.6%, 12/18) (P=0.002), and
metastatic cancer (88.8%, 8/9) (P,0.001) was statistically
significant but this was not the case in hyperplasia (20%, 2/10)
(P=0.477) (Fig. 1h).
Knockdown of NEFH Increases Tumor Growth
Since the NEFH promoter was specifically methylated in
tumor tissues and its expression was down-regulated in ESCC,
NEFH might function as a tumor suppressor in esophageal
cancer. In order to test this hypothesis, we first examined whether
knockdown of NEFH increased cell growth after establishing
NEFH shRNA stable clones in KYSE30 cells (Fig. S2a–S2c). A
significant increase in clonogenic cell growth was observed in
NEFH as a Tumor Suppressor
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Increased cell proliferation was also observed in N12 and N20
cells compared to control cells (C2) (Fig. 2b). Because cell
proliferation is closely linked to progression of the cell cycle, cell
cycle analysis was performed by flow cytometry. The population
of N12 and N20 cells residing in the G0/G1 phase yet decreased
in the G2 phase compared to C2 cells (Fig. 2c), indicating that cell
cycle progression through G0/G1 and then a block at G2
occurred from loss of NEFH. In addition, in vitro invasive activity
was increased in N12 and N20 cells (Fig. 2d). When cells were
incubated in 10% serum medium, the number of cells passing
intothe chamber increasedabout2.5- and 7-fold inN12 andN20
cells respectively, compared to C2 cells (Fig. 2d, left). Under HGF
treatment, the invasive activity of N12 and N20 cells increased
Figure 1. Analysis of NEFH methylation and expression in ESCC. a. Methylation status of the NEFH gene was examined by MSP with
methylation (M)- and unmethylation (U)-specific primers. PCR products were run on 4% agarose gels pre-stained with ethidium bromide. PN, paired
normal esophageal tissues from ESCC patients; PT, paired ESCC. Patients numbers are indicated. Corresponding normal tissues from patients 26, 45,
69, 46, and 53 were not available. Distilled water (DW) was used as a negative PCR control. L, 1 Kb Plus DNA ladder. Arrows, 100 bp. b, Scatter plots of
methylation values of NEFH in tissues and cell lines. The overall methylation value (TaqMan methylation values, TaqMeth V) is described in Materials
and Methods. Arrow, the optimal cut-off value for NEFH. *, Samples with a ratio equal to zero could not be plotted correctly on a log scale, so are
presented here as 0.01. All assays were performed in duplicate format, and experiments were repeated twice. Data showed reproducible and
concordant results in triplicate. Note, six ESCC tissues (8.7%, 6/69) harbored a 3-bp deletion that removes one amino acid (Ser45) in one of two
CTNNB1 alleles (data not shown). c, Quantitative evaluation of NEFH methylation levels showed that the NEFH methylation level (TaqMeth V) was
higher in ESCC (n=69) than in PN (n=20) (P,0.001, Wilcoxon-Mann-Whitney Test). d, ROC conveys the accuracy in distinguishing ESCC from PN in
terms of sensitivity and specificity. Area under ROC (AUROC) was over 0.93. Solid line, NEFH; dashed line, no discrimination. e, Expression of NEFH in
cell lines was examined by RT-PCR analysis. No basal expression of NEFH was seen in all ESCC cell lines except for KYSE30 (left) where baseline
expression was seen despite promoter methylation. NEFH methylation correlated tightly with loss of gene expression in most of the ESCC cell lines.
Silenced NEFH was reactivated after treatment with the demethylating agent, 5-Aza-dC, in 3 ESCC cell lines (KYSE30, KYSE410 and KYSE520) (middle).
Expression of NEFH in cDNA from ESCC tissue was barely detected by RT-PCR (right). b-actin was used as a loading control. m, no treatment. a, 5-Aza-
dC treatment. L, 1 Kb Plus DNA ladder. f, ESCC cell lines were treated with 5-Aza-dC and/or TSA, a histone deacetylase inhibitor. 1, no treatment; 2,
1 mM 5-Aza-dC; 3, 1 mM 5-Aza-dC + 300 nM TSA; 4, 5 mM 5-Aza-dC; 5, 5 mM 5-Aza-dC + 300 nM TSA. g, Expression of NEFH was compared between a
patient with ESCC and a patient without cancer (NN) (left), and in a pair of normal and tumor cDNA prepared from an ESCC patient (right) by real-time
RT-PCR. Fold induction was calculated by comparing the ratios of mRNA expression of NEFH to an internal control gene, 18 s rRNA. Experiments were
done in duplicate, and values indicate means 6 SD. h, IHC analysis of NEFH in esophagus cancer tissue array. a & b, PN and PT of an ESCC patient
(Grade I); c, normal esophagus tissue; d, chronic esophagitis; e, hyperplasia; f, ESCC-Grade I; g, ESCC-Grade III; h, basaloid ESCC; i, metastatic ESCC-
Grade I; j, metastatic ESCC-Grade II; k, metastatic ESCC-Grade III; l, adenocarcinoma-Grade II; m, adenocarcinoma-Grade III; n, metastatic
adenocarcinoma-Grade II. a , b were from ES241 and c , n were from ES804.
doi:10.1371/journal.pone.0009003.g001
Table 1. Immunohistochemical analysis of NEFH in esophageal cancer tissue microarray with normal tissue controls (ES804).
NEFH (+)% P value
Non-malignant Total 24/26 92.31
Normal 8/8 100.00
Chronic esophagitis 8/8 100.00
Hyperplasia Subtotal 8/10 20.00 0.477
Hyperplasia of epithelium 2/2 100.00
Atypical hyperplasia 6/8 75.00
Malignant Total 12/47 25.53
Adenocarcinoma Subtotal 5/20 25.00 ,0.001*
II 4/10 20.00
II-III, III 1/8 12.50
Adenosquamous carcinoma 0/1 0.00
Basaloid squamous cell carcinoma 0/1 0.00
Squamous cell carcinoma Subtotal 6/18 33.33 0.002*
I 4/11 36.36
I-II, II 1/4 25.00
III 1/3 33.33
Metastatic cancer Subtotal 1/9 11.11 ,0.001*
Metastatic adenocarcinoma 1/3 33.33
Metastatic squamous cell carcinoma 0/6 0.00
Expression level was indicated as -, absent or faint expression; +, moderate expression; ++, expression; +++, strong expression.
NEFH positivity (+) was counted in samples with over moderate expression.
P values from Fisher’s exact test performed in normal vs. hyperplasia, adenocarcinoma, squamous cell carcinoma, or metastatic cancer.
*P,0.05 considered significant.
doi:10.1371/journal.pone.0009003.t001
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right).
To examine the loss of NEFH in vivo, cells were subcutaneously
injected into the flanks of 6-week-old nude mice. Tumor
development was observed 10 days after injection in both flanks
injected with control or either N12 (n=6) or N20 cells (n=11). A
marked increase of tumor volume was observed in mice injected
with NEFH-knockdown cells (Fig. 2e–h). Tumor volume in the
mice injected with C2 cells did not change significantly for 4 weeks
after injection. IHC analysis confirmed decreased expression of
NEFH in N12- or N20 cells-grafted tumors (Fig. S2d). The
expression of proliferating cell nuclear antigen (PCNA), a marker
for cell proliferation, increased in N12 and N20 cells.
To examine the effects of increased NEFH expression on the
growth of esophageal cancer cells, the KYSE140 cell line was
selected due to its barely detectable basal expression of the NEFH
gene (Fig. 1e). KYSE140 cells with a higher level of NEFH did not
survive for longer than three weeks (data not shown), so transient
transfection was performed for NEFH gene delivery. We first
performed the MTT assay to compare cell growth with or without
expression of NEFH. The growth in cells expressing NEFH
decreased to 55% of control cells that exponentially grew for 3
days of incubation, (Fig. 2i)( P,0.05). We then performed the
colony focus assay. In control cells, KYSE140 exhibited strong
colony-forming ability with multiple colonies (125611.24 colonies)
(Fig. 2j). However, in pNEFH-transfected cells, a marked decrease
in colony numbers was observed (55.3366.43 colonies, 44% of
control) (P,0.001). These results indicate that forced expression of
NEFH suppresses cell growth.
To investigate whether NEFH had apoptotic activity, the
population of live and dead cells were determined by the trypan
blue exclusion assay. The population of non-viable, apoptotic cells
having blue cytoplasm was less than 2% in control cells, whereas
the population of non-viable cells in pNEFH-transfected cells
increased to 27% (Fig. 2k). The apoptotic cell population was
further assessed by flow cytometry after staining cells with Annexin
V-FITC and 7-AAD, based on the cell population in the top right
(late stage of apoptosis) and the bottom right quadrants (early stage
of apoptosis). A 15% increase in apoptotic cells was observed in
pNEFH-transfected cells compared to control with a distribution
shift toward increased apoptosis (Fig. 2l). Forced expression of
NEFH caused a 2-fold increase in the caspase23/7 activity
(Fig. 2m), but did not increase the caspase-9 activity (data not
shown). Western blot analysis showed increased levels of cleaved
PARP (C.PARP) and BAX, but decreased level of Bcl-2 in NEFH
expressing cells (Fig. 2n), indicating that the mitochondria-
mediated cell death pathway is activated by NEFH.
NEFH-Knockdown Stimulates b-Catenin-TCF/Lef
Signaling
Previous studies have shown that b-catenin-TCF/Lef signaling
is aberrant in esophageal carcinomas [48]. Phosphorylated Akt
triggers a network that positively regulates G1/S cell cycle
progression through inactivation of Gsk3b [49], direct phosphor-
ylation of b-catenin at Ser552, which enhances b-catenin nuclear
accumulation [50] and increased b-catenin-TCF/Lef transcrip-
tional activity [49]. Therefore, we investigated whether the
expression of Akt and its downstream effectors was affected by
NEFH down-regulation. Increased Gsk3b phosphorylation and
decreased total Gsk3b level were observed in N12 and N20
compared to C2 cells (Fig. 3a, left). The slight increase of total Akt
was due to increased Akt1 and Akt2 in N12 and N20 cells,
respectively (Fig. S3a–S3c).
Both Gsk3b and casein kinase-1 (CK1) phosphorylate b-catenin
at Ser33/Ser37/Thr41 and at Thr41/Ser45, respectively, leading
to the degradation of b-catenin through the ubiquitin pathway
[51,52]. In contrast, protein kinase A (PKA) phosphorylates b-
catenin at Ser675 to stabilize b-catenin, resulting in increased
cytoplasmic and nuclear b-catenin levels [53]. In NEFH down-
regulated cells, phosphorylation of b-catenin at Ser33/Ser37/
Thr41 and at Thr41/Ser45 decreased with a concomitant increase
of total b-catenin. In contrast, phosphorylation of b-catenin at
Ser675 increased in N12 and N20 cells.
Activation of the Akt oncogene is in part responsible for the
bioenergetic shift to dependence on glycolytic metabolism
characteristic of most malignant cells [54]. Akt also plays a vital
Figure 2. Down-regulation of NEFH increases tumor growth. a, Soft agar assays were performed with the stable cell lines. Colonies were
counted and photographed under a microscope after two weeks of cell culture. Scale bar, 500 mm. *, P,0.05 considered significant (T-test). b, Cellular
growth was evaluated by the MTT cell growth assay for 5 days. Data are expressed as absorbance at 570 nm and experiments were repeated twice in
triplicate. c, Representative images of cell cycle analysis. After serum starvation for 24 hrs, cells were released in 10% serum-medium for 24 hrs for cell
cycle transition. Cells were fixed, incubated in propidium iodide/RNase A solution, and analyzed by flow cytometry. Two independent experiments
were done and similar results were observed. d, Cells were incubated in 10% serum medium (upper left) or in 1% serum with HGF (100 ng/ml, upper
right) for 16 hrs, and the in vitro cell invasion assay was performed. HGF promotes cell migration of human ESCC [70]. After fixation and staining,
invading cells were counted at 40 X magnification (upper, left) or 100 X magnification (right). Cells were photographed at 40 X magnification (lower).
Scale bar, 200 mm. Cell growth for 16 hrs determined by MTT assay was not significant (data not shown). Two independent experiments were done in
triplicate, and values indicate means 6 SD. e, Knockdown of NEFH in tumorigenicity of KYSE30 cells. C2 cells were injected on the left and N12 or N20
cells were on right flank of each of 6-week-old nude mice, and the time course of tumor growth was measured twice a week for 4 weeks as described
in Material and Methods. Each point represents the mean volume 6 S.D. of tumor volumes of mice in each group. The variance of the tumor volume
in mice injected with N20 cells was smaller than in mice injected with N12 cells, suggesting that the N12 cells were probably a mixed population of
clones with different levels of NEFH knockdown. f, At day 27 after injection, mice were sacrificed and pictures were taken. Scale bar, 2.5 cm. Arrows
indicate tumor mass in individual mice. At day of 27, tumor mass was dissected from both flanks and tumor volume was measured (g). h,
Representative pictures for tumor mass. Scale bar, 2.5 cm. i, the MTT assay was performed in KYSE140 cell lines transiently transfected with an
expression vector carrying NEFH full-length cDNA (pcDNA3.1-NEFH, pNEFH) or a mock vector pcDNA3.1 (p3.1) as a control. Data are expressed as
absorbance at 570 nm and two independent experiments were done in triplicate. Values indicate means 6 SD. *, P,0.05 in T-test. j, Colony focus
assays were performed after transfection with NEFH in KYSE140. Cells were incubated in the presence of G418 (125 mg/ml) for two weeks and stained
with 0.4% crystal violet solution (MeOH/Acetic acid, 3:1). After air-drying, colonies were photographed under a microscope. Values are expressed as
means 6 SD and are derived from experiments done in triplicate. k, The trypan blue dye exclusion assay was performed to determine the number of
viable or apoptotic cells present in a cell suspension. Live cells that had intact cytoplasms (white) and apoptotic cells that did not (blue) were
counted, and data are presented as cell number per ml of cell suspension. Experiments were repeated twice in triplicate. l, Apoptosis was quantified
using the Annexin V analysis. Labeled cells were detected by Flow cytometry analysis. Cell distribution of NEFH-expressing cells was shifted toward
increased apoptosis. m, Caspase-3/7 activity was determined using luminescence (Luc)-based Caspase assay system. Cells were incubated for 72 hrs
after transfection. Experiments were repeated twice in triplicate. n, Western blotting of whole cell lysates extracted from KYSE140 cells 48 hrs after
transfection. C.PARP, cleaved PARP. b-actin was used as a loading control.
doi:10.1371/journal.pone.0009003.g002
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prevent the induction of apoptosis [55,56]. We thus further
elucidated expression level of proteins that play roles in the
glycolytic pathway and in mitochondrial function in NEFH-
diminished cells. M2-type pyruvate kinase (PK-M2) is a key
glycolytic enzyme, and pyruvate dehydrogenase (PDH) is a TCA
cycle enzyme converting pyruvate to acetyl-CoA in mitochon-
dria. PK-M2 and PDH are two of the enzymes that play a key
role in increasing glycolysis and lactate production. The protein
level of PK-M2 increased in N12 and N20 compared to C2 cells,
Figure 3. NEFH-knockdown stimulates b-catenin-TCF/Lef signaling. a, Total cell lysates extracted from C2, N12 and N20 cells were run on 4–
12% polyacrylamide gel and transferred onto nitrocellulose membrane. Membranes were then probed for expression of factors mediating b-catenin
signaling and down-stream target genes (left), and proteins functioning in glycolytic pathways and in mitochondrial function using individual specific
antibodies (right). No mutation was found in exon 3 of b-catenin in all 12 ESCC cell lines tested (data not shown), indicating that Gsk3b binding to b-
catenin is intact in these cell lines. b, Expression of proteins in NP-40-soluble (cytosolic) and -insoluble (nuclear) fractions. b-actin and nuclear protein
98 (NuP98) serve as loading controls for each fraction. c, TOPflash reporter activity. C2, N12 and N20 cells were transfected with either TOPflash or
FOPflash reporter plasmid. b-Catenin-TCF/Lef-mediated transcription was determined by the TOPflash luciferase activity. FOPflash contained mutant
TCF/LEF-1-binding sites and was used as control. Reporter activities were normalized to internal control Renilla. Two independent experiments were
done in triplicate, and values indicate means 6 SD. d, Western blotting of whole cell lysates extracted from KYSE140 cells 48 hrs after transfection.
doi:10.1371/journal.pone.0009003.g003
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glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was also
observed in N12 and N20 cells, but little difference was observed
in the expression of lactate dehydrogenase-A (LDHA), Hsp60, a
mitochondrial matrix protein, or mitochondrial H
+-ATP syn-
thase (b-F1-ATPase). Interestingly, c-Myc expression, which
increases mitochondrial biogenesis and cellular respiration
[57,58], was down-regulated after decreasing NEFH expression.
Similar results were observed in HEK293 cells transfected with
NEFH siRNA (Fig. S3d). In addition, to determine whether the
altered level of b-catenin phosphorylation affects the subcellular
localization of b-catenin, NP-40 soluble (cytosol) and insoluble
(nucleus) fractions were extra c t e df r o mC 2a n dN 2 0c e l l s .T h e
level of b-catenin increased in the nuclear fraction of N20 cells
(Fig. 3b), indicating increased stability of b-catenin in cells with
loss of NEFH.
The luciferase reporters, TOPflash and FOPflash, which have
either wild-type (TOP) or mutated (FOP) binding sites for the b-
catenin-TCF4/Lef complex, were used to characterize the
transcriptional activity of the b-catenin-TCF/Lef complex. These
reporter constructs were transfected into C2, N12 and N20 cells,
and the luciferase activity was determined. In C2 cells, TOPflash
activity was 2-fold higher than FOPflash activity, whereas a 6- and
5-fold increase of TOPflash activity was detected in N12 and N20
cells, respectively (Fig. 3c), indicating that NEFH loss increases the
transcriptional activity of the b-catenin-TCF/Lef complex. To
investigate whether down-regulation of NEFH alters b-catenin-
TCF/Lef-dependent transcription, the expression levels of cyclin
D1, TCF1, and MMP-7 were examined. We found that the
transcriptional levels of b-catenin, cyclin D1 and MMP-7 were
elevated significantly in N20 compared to C2 cells (Fig. S3e),
indicating that stimulation of b-catenin-TCF/Lef signaling by
NEFH down-regulation results in up-regulation of key target
genes.
We also tested protein expression in control and KYSE140 cells
expressing NEFH. While the level of total Akt was similar in the
two cell types, phosphorylated Akt was decreased by NEFH
(Fig. 3d). The levels of phospho-b-catenin
Ser675 and of total b-
catenin in both total cell lysates (Fig. 3d) and nuclear fraction were
decreased by NEFH (data not shown). In contrast, the expression
of Gsk3b, and phosphorylation of b-catenin
Ser33/Ser37/Thr41 and b-
catenin
Thr41/Ser45 were increased by NEFH. The expression of
cyclin D1 and MMP-7, downstream targets of b-catenin-TCF/Lef
signaling, were down-regulated by NEFH. In addition, an increase
of PDH and concomitant decrease of PK-M2 at the mRNA and
protein level were observed in NEFH-expressing cells (Fig. 3d and
Fig. S3f). These results indicate that the expression of proteins
involved in b-catenin-TCF/Lef signaling as well as levels of PK-
M2 and PDH are altered by NEFH.
Down-Regulation of NEFH Increases Mitochondrial
Dysfunction and Glycolysis
Preservation of cellular survival requires association of a series of
cellular survival pathways which are linked to the activation of
Wnt signaling and Akt for the maintenance of the mitochondrial
membrane potential. Akt has been coined the ‘‘Warburg kinase’’
and increased aerobic glycolysis is a common abnormality of
human cancer [59]. Mitochondrial membrane potential (Dym) is
known to be the driving force of mitochondrial ATP synthesis, and
a decrease in Dym contributes to the acquisition of a more
invasive cellular phenotype with reduced chemosensitivity [60].
To determine changes in Dym by NEFH down-regulation,
intracellular mitochondria were stained with the membrane
potential sensitive dye, JC-1, and fluorescence imaging was
performed by flow cytometry. The distribution of J-aggregates
(FL2-H channel, Red Flu) in N20 cells decreased compared to C2
cells whereas that of the JC-1 mononer (FL1-H channel, Green
Flu) increased, indicating decreased Dym in N20 cells (Fig. S4d
and S4e). The population of cells that resided at the top right (UR)
and the bottom right quadrant (LR) was compared in Quadrant
statistics. Cell population at the LR increased in N20 (2.34%)
compared to C2 cells (0.46%). These results indicate disruption of
the mitochondrial membrane potential by down-regulation of
NEFH.
A metabolic switch from mitochondria-based, oxygen-depen-
dent ATP production (oxidative phosphorylation) to aerobic
glycolysis leads to oxygen- and mitochondria-independent ATP
generation, which is a hallmark of aggressive cancer growth [38].
To determine whether the reduction in Dym associated with
NEFH loss reflects a reduction in respiration, the cellular O2 level
was measured. As compared to C2 cells, we observed a decrease of
cellular O2 consumption (-DO2) in N12 and N20 cells with a slow
slope in O2 reduction as a function of time (Fig. 4a). Measurement
of intracellular ATP content revealed reduced ATP synthesis in
N12 and N20 cells (40% decrease) (Fig. 4b). Energy production by
O2 consumption is required for cell survival, but dysfunctional
mitochondria generate reactive oxygen species (ROS), resulting in
cell dysfunction or death. The level of ROS was measured using a
fluorescent dye, DCDHF-DA. The baseline ROS level in both
N12 and N20 cells was about 65% of that in C2 cells (Fig. 4c). To
investigate cell response to oxidative stress, cells were exposed to
H2O2 in serum-free conditions for 2 hrs, and the ROS level was
immediately measured. The distribution of ROS in C2 cells was
shifted toward increased ROS by H2O2 treatment, whereas little
change in N12 and N20 cells was observed. In separate
experiments, cells were exposed to different concentrations of
H2O2, and the ROS level was measured after 24 hrs of recovery.
Consistent results were observed in N20 cells that exhibited
reduced level of ROS compared to control (Fig. 4d). These results
highlight that the cellular capacity to remove ROS increases when
NEFH is lost, possibly resulting in increased resistance to oxidative
stress (See Figure S4a–S4c).
The metabolic shift results in increased lactate production via
cycling through the pentose phosphate pathway, and plays an
important role in malignant transformation of cancer cells. We
thus collected growth medium from cell culture for examination of
lactate and glucose levels. An increase of over 40% in lactate
production and glucose consumption was observed in N12 and
N20 cells (Fig. 4e). Taken together, loss of NEFH expression
resulted in decreased ROS production and increased aerobic
glycolysis.
Since cellular respiration and glycolysis were deregulated by
NEFH down-regulation, we examined the influence of NEFH
expression on mitochondrial function and glycolysis. Lactate levels
and glucose consumption were reduced by NEFH expression
(Fig. 4f). In contrast, NEFH did not affect energized mitochondria
(red fluorescence, J-aggregates), but increased the level of JC-1
monomers (green fluorescence); Dym decreased in NEFH-
transfected cells (Fig. 4g). The population of control cells in the
bottom right quadrants (LR) was 4.15%, and increased to 9.15%
in NEFH-transfected cells (data not shown). Significant increases
of oxygen consumption and ATP generation were observed in
NEFH-transfected cells (Fig. 4h), whereas oligomycin, an inhibitor
of mitochondria H
+-ATPase, inhibited the NEFH-increased
oxygen consumption and ATP generation. Concomitantly, a 3-
fold increase of ROS level was observed (Fig. 4i). These results
indicate that NEFH regulates mitochondrial function, leading to
alterations of cellular respiration and glycolysis.
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PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9003Figure 4. Increase of mitochondrial dysfunction and glycolysis by decreased NEFH. a, Cells were incubated with a Clark-type electrode to
measure O2 concentration as a function of time (right) and to calculate rates of O2 consumption (-DO2, nmol/min/10
7) (left). b, ATP level was
measured using an equal number of cells (nmol/ml/10
6), and data are presented as relative fold compared to control. c, Representative results of ROS
imaging with fluorescent intensity in each cell line (three in the left). The ROS level in cells was measured using DCDHF-DA fluorescent dye, and
analyzed by flow cytometry. Cells were treated with H2O2 (100 mM) in serum-free medium for 2 hrs, and ROS levels were immediately measured
without recovery. Relative fold values were calculated, and experiments were repeated twice in triplicate. Values indicate means 6 SD (far right). d,
Cells in culture were exposed to different concentrations of H2O2 (0 , 1 mM), and ROS levels were measured after 24 hrs of recovery in complete
growth medium. Cells were analyzed using a fluorescence microplate reader and fluorescence was acquired at 495/525 (ex/em). e, Lactate production
(left) and glucose concentration (right) were measured in cell culture medium and the MTT assay was performed for verifying equal number of cells,
and no significant difference was found (data not shown). f, Glucose concentration (upper) and lactate production (lower) were measured in cell
culture medium 24 hrs after transfection of pNEFH or p3.1 vector into KYSE140 cells. g, Dym was determined after staining cells with a membrane
potential sensitive dye, JC-1. Fluorescence intensity was acquired by reading cells in a fluorescence microplate reader. Values are expressed as means
6 SD, and experiments were done in triplicate. h,O 2 consumption (upper) and ATP synthesis (lower) were increased by NEFH expression in KYSE140
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PDH and PK-M2
Gsk3b is a key enzyme that phosphorylates b-catenin at NH2-
terminal serine threonine residues. Gsk3b inactivation is mediated
mainly by two pathways: 1) activation of growth factor receptors
by EGF, platelet-derived growth factor or insulin, leading to
activation of Akt, a protein kinase that phosphorylates and
inactivates Gsk3b, 2) activation of the Wnt pathway leading to
inhibition of Gsk3b. To investigate whether the Akt-b-catenin
pathway is involved in the regulation of PK-M2 and PDH, each
siRNA pool targeting PTEN, Gsk3b, b-catenin, or a non-targeting
control was transfected into C2 and/or N20 cells, and western blot
analysis was performed 48 hrs after transfection. As shown in
Figure 5, more than 90% of each endogenous gene level was
knocked down by the transfection. Activation of Akt with
increased expression of b-catenin and PK-M2 was observed in
C2 cells with PTEN gene knockdown (Fig. 5a, left). Gsk3b
knockdown slightly increased the expression of PK-M2 in N20
cells, but not in C2 cells (Fig. 5a, right), indicating differences in
knockdown efficiency of Gsk3b or the presence of Gsk3b-
independent PK-M2 regulation in C2 cells. However, PDH
expression was decreased by PTEN or Gsk3b siRNA transfection.
In addition, b-catenin knockdown reversed the increased PK-M2
expression, and reversed the decreased level of PDH in N20 cells
(Fig. 5b, left). Next, we transfected the pCI-b-cat plasmid
expressing wt-b-catenin or mock control into KYSE140 cells
and compared expression levels of PK-M2 and PDH. Over-
expression of b-catenin increased PK-M2 but decreased PDH
levels (Fig. 5b, right). These results indicate that PK-M2 and PDH
are downstream effectors of the Akt-b-catenin pathway signaling
in N20 cells.
To further elucidate whether b-catenin is required for the
regulation on PK-M2 and PDH by NEFH, N20 cells were
transfected with b-catenin or control siRNA and incubated for
48 hrs. Cells were then subsequently transfected again with
pNEFH and p3.1, and incubated for a further 48 hrs. b-catenin
levels remained down-regulated during 96 hrs of incubation after
transfection (Fig. 5c, left). The up-regulated PDH by b-catenin
knockdown was not further enhanced by the overexpression of
NEFH, indicating that b-catenin is required for the inverse
regulation of PK-M2 and PDH by NEFH. Moreover, KYSE140
cells were transfected with pNEFH or p3.1 and incubated for
24 hrs, and then transfected again with pCI-b-cat and incubated
for a further 48 hrs. Even though b-catenin was forcibly expressed,
its level was not higher than that of control, suggesting that the
marked expression of NEFH possibly inhibits ectopic expression of
b-catenin (Fig. 5c, right). No increase of PK-M2 and no decrease
of PDH were observed in pCI-b-cat transfected cells. However,
when KYSE140 cells were transfected with a b-catenin mutant
(pCI-b-cat-S33Y) that has a defect in Gsk3b-dependent phos-
phorylation of b-catenin, NEFH could not suppress mt-b-catenin
expression. Consequently, an increase of PK-M2 and a decrease of
PDH were observed in the cells transfected with pCI-b-cat-S33Y.
These results suggest that Gsk3b-dependent degradation of b-
catenin contributes at least part to the tumor suppressive role of
NEFH.
To examine whether b-catenin affects mitochondrial function, a
siRNA pool targeting b-catenin or a non-targeting control was
transfected into both C2 and N20 cells, and O2 consumption and
ATP synthesis were examined 72 hrs after transfection. The
reduced O2 consumption and ATP level in N20 cells were
increased by b-catenin knockdown (Fig. 5d and 5e). However, Dym
(Fig. S5a) and ROS level (data not shown) were not influenced by
the b-catenin knockdown in both C2 and N20 cells. The increased
lactate concentration in N20 cells returned to the level of C2 cells
by b-catenin knockdown (Fig. 5f ). In 24 hrs, cell viability was not
significantly decreased by the low expression of b-catenin, but
inhibition of cell growth by b-catenin knockdown was observed
after 3 days of incubation (Fig. S5b). These results suggest that b-
catenin causes mitochondrial dysfunction in NEFH down-
regulated cells by inverse regulation of PDH and PK-M2.
NEFH Down-Regulation Increases Cellular Sensitivity to
Glycolysis Inhibitors
To suppress the cellular glycolytic pathway, cells were treated
with different concentrations of 2-deoxyglucose (2-DG), an
inhibitor of glucose metabolism, or were exposed to glucose-free
conditions for 24 hrs, and cell viability was examined. Glucose
withdrawal did not make a significant difference in cell viability
between C2 and N20 cells (50% of untreated control). However,
reduction in the cell viability in N20 cells was significantly
enhanced by 2-DG (Fig. S6a).
Activation of PI3K/Akt and NF-kb increases the overall rate of
glycolysis and cell survival [54,61]. To examine whether the
inhibition of these pathways could suppress cell growth, cells were
treated with LY294002 (10 mM), a reversible PI3K inhibitor, API-
2 (10 mM), an Akt inhibitor, and QNZ (50 mM), a NF-kb inhibitor,
for 20 hrs. As shown in Figure S6b, N20 cells were more sensitive
to these inhibitors than C2 cells. Among these inhibitors, API-2
was the one that could block Akt activation in both C2 and N20
cells (Fig. 6a). QNZ even increased Akt phosphorylation in C2 cells
and more dramatically in N20 cells. LY294002 and Wortmannin
(1 mM), an irreversible PI3K inhibitor, had little influence on
phospho-Akt levels in N20 cells (Fig. S6f ). In C2 cells, the Akt
level was increased by all of these inhibitors but little difference
was observed in PK-M2 and PDH levels compared to untreated
control. In N20 cells, the levels of Akt, b-catenin and PK-M2 were
decreased, but the expression of Gsk3b and PDH were increased
by the treatment of these inhibitors. Interestingly, decrease of
Gsk3b phosphorylation and increase of b-catenin phosphorylation
at Ser33/Ser37/Thr41 and at Thr41/Ser45 were caused only by
API-2. In addition, b-catenin phosphorylation at Ser675 and PK-
M2 expression were most decreased by API-2. Therefore, API-2
was most effective at inhibiting Akt-b-catenin signaling among the
three inhibitors tested. Moreover, a decrease of Gsk3b phosphor-
ylation and an increase of PDH by 2-DG treatment occurred
specifically in N20 cells. The complete abolishment of PK-M2 by
treatment with 2-DG was observed only in N20 cells, and thus, 2-
DG and API-2 were selected for further study.
Treatment with 2-DG or API-2 in N20 cells markedly
decreased anchorage-independent cell growth (Fig. 6c). The
lactate concentration after 8 hrs of treatment significantly
decreased (Fig. 6d), whereas ROS levels increased in N20 cells
(Fig. 6e and Fig S6d). The treatment of 2-DG or API-2 in N20 cells
had little effect on O2 consumption or ATP synthesis (Fig. S6c).
Interestingly, alterations in Dym by 2-DG or API-2 treatment
cells. *, P,0.05 compared to KYSE140 cells transfected with p3.1; **, P,0.05 compared to cells transfected with pNEFH without treatment of
oligomycin (2.5 mM), an inhibitor of mitochondrial H
+-ATPase. i, ROS levels were measured using DCDHF-DA fluorescent dye, and analyzed by flow
cytometry. Relative fold values were calculated and indicated as means 6 SD (upper). Representative results of ROS imaging with fluorescent
intensity (lower).
doi:10.1371/journal.pone.0009003.g004
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PLoS ONE | www.plosone.org 10 February 2010 | Volume 5 | Issue 2 | e9003Figure 5. PK-M2 and PDH are regulated through the Akt-b-catenin pathway. a, siRNA of PTEN (left), Gsk3b (right) or a non-targeting control
was transfected into C2 and/or N20 cells and Western blot analysis was performed 48 hrs after transfection. b-actin was used a loading control. b,
Left, Cell were transfected with b-catenin or non-targeting control siRNA. For b-catenin detection, exposure time of the protein membrane on X-ray
film was 5 sec (short) and 1 min (long) after extensive washing. Right, Expression levels of PK-M2 and PDH were compared in KYSE140 cells
transfected with pCI-b-cat expressing wild-type b-catenin or mock plasmid. c, Left, N20 cells were transfected with b-catenin or control siRNA and
incubated for 48 hrs. Cells were then transfected again with pNEFH and p3.1 (10 mg each), incubated for another 48 hrs, and Western blot analysis
was performed. Right, KYSE140 cells were transfected with pNEFH and incubated for 24 hrs, and then transfected again with pCI-b-cat or pCI-b-cat
(S33Y) that expresses a constitutively active form of b-catenin, and incubated for another 48 hrs. d, C2 and N20 cells were transfected with b-catenin
or non-targeting control siRNA, and incubated for 48 hrs. After trypsinization, cells were incubated with a Clark-type electrode to measure O2
concentration as a function of time (left) and to calculate rates of O2 consumption (-DO2, nmol/min/10
7) (right). Values are expressed as means 6 SD
and experiments were repeated twice in duplicate. *, P,0.05 compared to C2 cells transfected with control siRNA. **, P,0.05 compared to N20 cells
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(Fig. 6f, box); in C2 cells, few changes in the distribution of J-
aggregates (FL2-H channel) or JC-1 monomers (FL1-H channel)
were observed (Fig. 6f ). In contrast, the distribution of J-
aggregates in N20 cells was markedly shifted toward more
energized mitochondria by 2-DG or API-2 treatment, whereas
that of JC-1 monomers was decreased. These results indicate that
cancer cells with loss of NEFH are more susceptible to inhibitors
that decrease Akt activation and glycolysis.
Discussion
Increased expression and nuclear localization of b-catenin
protein were reported in ESCC [27,31–33]; however, the
mechanism of b-catenin accumulation was unknown in the
absence of mutations of either b-catenin or the adenomatous
polyposis coli (APC) [27–30]. Here, we show that NEFH is a
tumor suppressor gene, and that promoter methylation of NEFH
gene decreases gene expression and increase the activity of b-
catenin. Even though precise mechanisms on how NEFH regulates
b-catenin are still needs to be further elucidated, epigenetic
silencing of the NEFH gene in ESCC seems to be responsible for
increased b-catenin expression, leading to activation of b-catenin/
TCF-dependent transcription and key downstream effectors,
leading to ESCC tumorigenesis.
The nuclear localization of b-catenin is controlled by its
phosphorylation state at NH2-terminal serine threonine residues
regulated by Gsk3b [62]. Phosphorylation of b-catenin by Gsk3b
targets b-catenin to ubiquitination and proteasome degradation.
Thus, activation of the pathway represses b-catenin degradation,
resulting in nuclear accumulation of b-catenin. In the nucleus, the
b-catenin-TCF/Lef complex activates target genes such as c-Myc
and cyclin D1, which are involved in oncogenic transformation
[4,20–26]. Previous studies have shown that TCF-dependent
transcriptional activity in ESCC cell lines are increased by mutant
b-catenin as compared to wild-type counterparts [24]. Our results
clearly show increased b-catenin/TCF-dependent transcriptional
activity in NEFH-deficient cells.
Increased aerobic glycolysis is a common abnormality, and
alteration of the bioenergetic phenotype of mitochondria is a
hallmark of esophageal cancer. When cancer cells generate ATP
due in part to mitochondrial respiration injury, they adapt
alternative metabolic pathways, such as increasing glycolytic
activity, to maintain their energy supply (the Warburg effect).
Oncogenic alterations that increase Akt kinase activity stimulate
aerobic glycolysis (increased glucose transport and lactate
production [54,59,63], but reduce the cellular activity of
mitochondria in many cancers [64,65]. However, the molecular
pathways underlying alterations in energy metabolism and
increased dependency on glycolysis have not been fully delineated.
Since malignant cells are highly dependent on the glycolytic
pathway for survival and the metabolic alterations make cells
resistant to therapeutic agents, understanding and targeting this
pathway is an important therapeutic strategy. Several agents
including 2-deoxyglucose, have been known to abolish ATP
generation through the glycolytic pathway.
In the present study, we demonstrated that loss of NEFH
resulted in a Akt-b-catenin-dependent reprogramming of glucose
and energy metabolism that included increased glycolysis
accompanied by a reciprocal decrease in cellular respiration.
NEFH could suppress PK-M2 and induce PDH when wt-b-
catenin was expressed in NEFH-deficient cells whereas NEFH
could not inhibit the activity of b-catenin mutated in the Gsk3b-
targeting Ser33 region. These results indicate that PDH induction
and PKM2 repression by NEFH are mediated through Gsk3b-
mediated degradation of b-catenin.
We found that b-catenin was required for the inverse regulation
of PK-M2 and PDH by cooperating with deregulated NEFH.
Interestingly, we found potential TCF-binding elements (TBE) in
the PK-M2 and PDH promoters. Five TBE were located 3-Kb
upstream of the TSS in the PDH promoter, and three TBE 5-Kb
upstream of the TSS in the PK-M2 promoter. Sequences of these
TBE matched the consensus for TCF-binding CTTTG(A/T)(A/
T) or the inverted sequences (A/T)(A/T)CAAAG [66,67];
CTTTGAT (2639 bp), CTTTGAA (21342 bp), CTTTGAA
(21355 bp), CTTTGTA (22148 bp) and an inverted match
TTCAAAG (22921 bp) in the PDH promoter, and three inverted
matches TACAAAG (23374 bp), TTCAAAG (23859 bp), and
AACAAAG (24836 bp) in the PK-M2 promoter. These results
suggest that PDH and PK-M2 may be targets of b-catenin-TCF/
Lef signaling. Future work will elucidate whether the sequences
and position of these TBE determine responsiveness to b-catenin/
TCF for PDH and PK-M2.
NEFH deficiency increases cellular resistance to oxidative stress
(H2O2) and the mitochondrial membrane potential disrupting
agent (Valinomycin) (Fig. S4a–S4c), but increases cellular sensitiv-
ity to 2-DG, a glycolysis inhibitor. Akt/protein kinase B signaling
inhibitor-2 (API-2, Triciribine), which is currently in clinical trials
[68] also inhibits glycolysis without affecting cellular respiration.
Previous results showed that API-2 inhibits Akt2 activation and
harbors anti-tumor activity against tumors with activated Akt [68].
Consistently, we observed increased expression of Akt2 in a clone
of NEFH-deficient ESCC cells (N20), and inhibition of anchorage-
independent cell growth by API-2. Akt was activated by 2-DG
treatment in both C2 and N20 cells (data not shown), but it is
unrelated to glycolysis inhibition of 2-DG [69]. Therefore, a
combination of API-2 in 2-DG-based therapy might further
improve the therapeutic efficacy of 2-DG-mediated growth
inhibition.
In addition, mitochondrial metabolism and biogenesis are
actively repressed in ESCC cells with loss of NEFH. NEFH loss
activates Akt, and further inhibits the activity of Gsk3b, leading to
expression of b-catenin in ESCC. Subsequently, Akt/b-catenin
signaling positively regulates PK-M2 expression and negatively
regulates PDH expression, which might further promote the
progression of ESCC. These findings indicate the involvement of
the Akt/b-catenin pathway directly in mitochondrial function and
identify a new regulatory network that inhibits mitochondrial
respiration. Moreover, other major cancer types display NEFH
promoter methylation (data not shown). Specific targeting of
cellular survival and stress resistance due to NEFH deficiency
represents a new rationale therapeutic strategy in human cancer.
Methods
Cell Lines and Tissues
Twelve ESCC cell lines, TE1, TE2, TE3, TE4, TE5, KYSE30,
KYSE70, KYSE140, KYSE150, KYSE200, KYSE410, and
transfected with control siRNA. e, ATP level was measured using an equal number of cells (nmol/ml/10
6), and data are presented as a relative fold
value compared to control. f, For the lactate assay, cells were incubated for 24 hrs after transfection, and cellular lactate level was measured in the cell
culture medium.
doi:10.1371/journal.pone.0009003.g005
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Biomedical Research Institute, Department of Aging and Cancer,
Tohoku University (TE series) and kindly provided by Dr.
Shimada in the Department of Surgery, Kyoto University (KYSE
series). Cells were grown in RPMI 1640 medium (2 mg/ml D-
glucose) supplemented with 10% fetal bovine serum. HEK293
were obtained from ATCC and grown in DMEM supplemented
with 10% FBS. SH-SY5Y human neuroblastoma cells were grown
in Phenol red-free RPMI1640 medium containing 10% FBS and
1% MEM non-essential amino acids. Twenty paired ESCC and
normal esophagus (patient No. 1–20) tissues were obtained from
the Gastroenterology Division, Department of Medicine, Univer-
sity of Maryland. Forty-nine cases of primary ESCC genomic
DNA and six ESCC tissue cDNA (patient No. 81–86) were
obtained from patients who underwent surgery at the Medical
Institute of Bioregulation Hospital, Kyushu University and the
Saitama Cancer Center. Fifteen normal esophageal epithelial
tissues (NN) were obtained from patients without cancer at
Department of Pathology, The Johns Hopkins University.
Written informed consent was obtained from the patients who
provided tissue DNA, and this study was approved by the
Institutional Review Board of the Johns Hopkins University.
Bisulfite Treatment, Sequencing, Conventional methylation-
specific PCR and Quantitative methylation-specific PCR (Taq-
Man-MSP) are described in the Text S1 with the criteria to
determine methylation in cell lines and tissues. Primer sequences
are shown in Table S4.
5-Aza-dC/TSA treatment, RT-PCR and Quantitative RT-
PCR are described in the Text S1.
Immunohistochemistry
Three ESCC tissue arrays; esophagus cancer test tissue array
with self-matching normal adjacent tissue (ES241), esophagus
cancer with matched normal adjacent tissue array (ES801) and
esophagus cancer progression tissue array containing normal,
inflammation, hyperplasia, squamous and adenocarcinoma
(ES804) were purchased from Biomax Inc. (Rockville, MD). After
deparaffinization and re-hydration, tissue slides were incubated
with anti-NEFH rabbit polyclonal antibody (1:150 dilutions,
Figure 6. ESCC cells with loss of NEFH are susceptible to
inhibition of glycolysis. a & b, Expression levels of downstream
effectors after treatment with 2-DG (1 mg/ml) or API-2 (10 mM) for
24 hrs. c. Cells were incubated in the complete growth medium
containing 2 mg/ml of D-glucose (RPMI 1640 medium) in the presence
of 2-DG (1 mg/ml) or API-2 (10 mM). 2-DG or API-2 was treated three
times a week for two weeks, and colonies were counted and
photographed under a microscope. Values are expressed as means 6
SD and experiments were repeated twice and done in triplicate. *,
P,0.05. Scale bar, 500 mm. d, Since cell death can skew the results, 2-DG
and API-2 treatments were limited to 8 hrs, and lactate production was
measured in the cell culture medium. Cell growth for 8 hrs determined
by the MTT assay was not significant (Fig. S6e). e, Cellular ROS levels
were measured after treatment of 2-DG or API-2 using DCDHF-DA
fluorescent dye, and analyzed by flow cytometry. Values are expressed
as means 6 SD and two independent experiments were done in
triplicate. *, P,0.05. f, Dym was determined after staining cells with a
membrane potential sensitive dye, JC-1 and analyzed by Flow
cytometry. Box, The ratio of red (J-aggregates) and green (JC-1
monomer) fluorescence intensity. Values are expressed as means 6
SD, and experiments were done in triplicate. *, P,0.05. g, b-catenin
signal pathway in ESCC. NEFH loss after promoter methylation activates
Akt that inhibits Gsk3b. Subsequently, increased b-catenin induces b-
catenin/TCF-depenendent transcription [29], leading to transcription of
specific genes which are involved in mitochondrial function and
glycolysis, such as PDH and PK-M2.
doi:10.1371/journal.pone.0009003.g006
NEFH as a Tumor Suppressor
PLoS ONE | www.plosone.org 13 February 2010 | Volume 5 | Issue 2 | e9003Sigma-Aldrich) at 4uC overnight. Secondary antibody was used at
a dilution of 1:500 and incubated for 1 hr. After washing, tissues
were stained with freshly prepared DAB solution (DAKO,
Carpinteria, CA). Control tissue was incubated with a rabbit
IgG control. Sections were counterstained in Mayer’s Hematoxy-
line (Sigma-Aldrich).
Establishment of shRNA Stable Cell Lines
Stable transfectants expressing siRNA targeting NEFH and
non-targeting control were constructed in KYSE30 cells. The
GIPZ lentiviral shRNAmir plasmid targeting NEFH and non-
silencing verified negative control plasmid (Openbiosystems,
Huntsville, AL) were transfected using Arrest-In
TM transfection
reagent according to the manufacturer’s protocol. Puromycin-
resistant control or NEFH shRNA clones were selected according
to tGFP expression under fluorescence microscope (Nikon TE200,
HG-100W mercury lamp) for establishing stable cell lines. Finally,
a control (C2) and two NEFH shRNA clones (N12 and N20) were
selected based on the expression of NEFH which was confirmed
by RT-PCR, real time-RT-PCR, green fluorescence imaging and
western blotting.
Mouse Xenograft Assay
Athymic nude mice were divided into two groups (n=6 for the
C2 vs. N12 group, and n=11 for the C2 vs. N20 group) and
injected subcutaneously on the left (C2 cells) and right (N12 or
N20 cells) flanks with 5 X 10
6 cells/200 ml PBS per flank by using
a 1-ml syringe fitted with a 27-gauge needle. Tumor size was
documented by direct measurement in two directions by using
Pro-Max calipers (Fowler Instruments, Newton, MA), and the
measurements were recorded as tumor volumes (V, mm
3). Tumor
volume was calculated by the equation of V=( LXS
2)/2, (L, long
diameter, S, short diameter), and was measured twice a week.
Statistical significance was determined with a T-test. All animals
were maintained in accordance with the guidelines of the Johns
Hopkins University Animal Care and Use Committee and the
National Research Council.
Construction of NEFH Expression Plasmid and
Transfection
The NEFH-pCMV-SPORT6 clone was purchased from
ATCC (Manassas, VA), and digested serially with EcoR1 and
Xba1. The insert was subcloned into pcDNA3.1 after digestion of
pcDNA3.1 with the same enzymes. Cells were transfected using
Fugene-6 (Roche, Basel, Switzerland) in OPTI-MEM (Invitro-
gen) or using Amaxa nucleofector II system (Amaxa Inc.
Gaithersburg, MD) per the manufacturer’s instructions. The
expression of NEFH in the cell line was confirmed by RT-PCR,
real time RT-PCR, and Western blot analysis 48 or 72 hrs after
transfection. Cells were plated on 24-well plates at a density of 3
X1 0
4 cells/well and incubated overnight at 37uC. Next day, cells
were transfected with 0.5 mg of pNEFH or mock vector. After
incubation for 72 hrs, the tetrazolium-based cell viability (MTT)
assay was performed.
Mitochondrial Membrane Potential (Dym)
Fluorescence imaging was performed by staining mitochondria
with the membrane potential sensitive dye JC-1 (Invitrogen). After
incubation with JC-1 (30 min at room temperature), mitochondria
were washed to remove excess dye by a gentle centrifugation step
(3 min at 2000 x g). For measuring the mitochondrial membrane
potential (Dym), fluorescence was acquired by flow cytometry:
green fluorescence at FL1-H channel and red fluorescence at FL2-
H channel. The ratio of red to green fluorescence was calculated
for Dym. As an alternative, cells (5 610
4 cells) in attachment in
96-well culture plate were assayed using a fluorescence microplate
reader (Molecular Devices) and fluorescence was acquired at 490/
530 (ex/em) for JC-1 monomers and 525/590 (ex/em) for J-
aggregates. Dym was calculated using the ratio of fluorescence of
J-aggregates to JC-1 monomers.
Total Cellular Oxygen Consumption and ATP Production
Equal numbers of cells (6 6 10
6) were suspended in 600 mlo f
growth medium and transferred into the chamber of an Oxytherm
electrode unit (Hansatech Instrument Ltd.), which uses a Clark-
type electrode to monitor the dissolved oxygen concentration in
the sealed chamber over time. The data were exported to a
computerized chart recorder (Oxygraph, Hansatech Instrument
Ltd.), which calculates the rate of O2 consumption (nmole/min/
10
7). The temperature was maintained at 37uC during the
measurement. Intracellular ATP levels were measured for an
equal number of cells (2 610
5) using an ATP assay kit (Sigma)
according to the manufacturer’s instructions. After addition of the
assay mixture containing luciferin and luciferase, luminescence
was measured immediately using a Wallace microplate lumines-
cence reader (Perkin Elmer, Waltham, MA). Results are presented
as arbitrary fold.
Reactive Oxygen Species
The level of ROS in cells was measured using 5-(and-6)-
chloromethyl-29,79-dichlorodihydrofluorescein diacetate, acetyl
ester (DCDHF-DA) (Invitrogen). In brief, cells were incubated
with 2.5 mM DCDHF-DA for 30 min at 37uC. After trypsiniza-
tion, single cell suspensions were subjected to flow cytometry. As
an alternative, cells in culture plate were assayed using a
fluorescence microplate reader and fluorescence was acquired at
495/525 (ex/em).
Glucose Consumption and Lactate Production
Cells were seeded at a density of 1 6 10
5/well and incubated
overnight. Culture medium was changed with fresh, growth
medium before further incubation for 16 hrs. The culture medium
was then collected, and filtered through a 0.22 mm pore
membrane. Glucose and lactate levels were measured using
glucose and lactate assay kits as manufacturer’s instructions
(Biovision, Exton, PA). Glucose consumption was determined
from the difference in glucose concentration compared with
control. A MTT assay was performed to verify equal number of
cells, and no significant difference was found (data not shown).
Luciferase Reporter Assay
b-catenin/Tcf transcriptional reporter activity was performed as
described by using TOPflash/FOPflash TCF Reporter Kit (Upstate
Biotechnology, Lake Placid, NY). TOPflash has four copies of wild-
typeTcf binding site, and FOPflash has three copies of mutant TCF
binding site upstream of the E1B TATA box and Luciferase open
reading frame. FOPflash was used as a control for measuring
nonspecific activation of the reporter. Cells were transfected with
reporter plasmid (0.1 mg) and a Renilla luciferase (pSV-Renilla,
0.02 mg (Promega) (an internal control for transfection efficiency)
using FuGene HD reagent (Roche, Indianapolis, IN). After 48 hrs
of incubation, the reporter activity was measured using the Dual-
luciferase reporter assay system (Promega). Relative luciferase
activity (arbitrary units) was reported as fold induction after
normalization for transfection efficiency. Transfections were
performed in triplicate and repeated twice to ensure reproducibility.
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Whole cell lysates extracted in RIPA buffer were separated on
4–12% gradient SDS-PAGE and transferred to nitrocellulose
membrane. The blots were incubated with specific antibodies for
each gene for 2 h at room temperature or 4uC overnight. After
antibody washing, the blots were reacted with their respective
secondary antibody and detected with enhanced chemilumines-
cence reagents (Amersham, Pittsburgh, PA) according to the
supplier’s protocol. Antibodies specific for NEFH recognizing both
dephosphorylated and phosphorylated form of NEFH and for b-
actin were purchased from Sigma. All antibodies were purchased
from Cell Signaling Technologies (Beverly, MA) except for the
anti-Hsp60, anti- mitochondrial H
+-ATPase, anti-nuclear protein
98, and anti- PDK1 antibodies (Stressgen, British Colombis,
Canada). Anti-PK-M2 antibody was from Abnova (Walnut, CA),
anti-bcl-2 antibody from Santa Cruz Biotechnologies (Santa Cruz,
CA), and anti-Bax antibody from Neomarkers (Fremont, CA).
Knockdown of PTEN, Gsk3b and b-Catenin
A siRNA pool targeting PTEN, Gsk3b and b-catenin were
purchased from Dharmacon, and transfected into C2 and/or N20
cells as described. Cells were incubated for 48 hrs after
transfection, and total cellular oxygen consumption, ATP
production, Dym, ROS level, lactate production were examined.
For the lactate assay, cells were incubated for 24 hrs and cell
culture medium was collected. pCIneo-b-cat expressing wild-type
b-catenin and pCIneo-b-cat-S33Y expressing mutant b-catenin
that has a defect in Gsk3b-dependent phosphorylation of b-
catenin was kindly given by Dr. Bert Vogelstein from the Johns
Hopkins University.
Statistical Analysis
We used the methylation levels (TaqMeth V) for NEFH to
construct Receiver Operating Characteristic (ROC) curves for the
detection of ESCC. In the ROC analysis, a tangent point where
the slope of the ROC curve was 1.00 has been selected as an
optimal cut-off point to balance sensitivity and specificity. P value
was derived from Z value that was calculated from the equation of
(AUROC-0.5)/Std Err (standard error of AUROC). Using this
approach, the AUROC (Area under ROC) identified optimal
sensitivity and specificity levels (i.e., cut-offs) to distinguish normal
from malignant ESCC tissues. The cut-off value (0.985) deter-
mined from the ROC curve was then applied to determine the
frequency of gene methylation. Samples with a methylation level
higher than the cut-off were designated as methylated, and
samples with a methylation level lower than the cut-off were
designated as un-methylated. The significance level used was 0.05
and all statistical analyses were conducted using STATA Version 9
(STATA Inc., College Station, TX).
Supporting Information
Text S1
Found at: doi:10.1371/journal.pone.0009003.s001 (0.07 MB
DOC)
Figure S1 Analysis of NEFH methylation in ESCC. a, One
dense CpG island (colored area) resides 300 bp upstream of the
TSS in the promoter region of NEFH and another 1.1 Kb
downstream of the TSS. Primers for bisulfite-sequencing (Bi-F1
and Bi-R1), MSP and TaqMan-MSP were designed within the
region which covered most of the CpG-rich region proximal to the
TSS ({similar, tilde operator } 400 bp) in the NEFH promoter. F,
forward; R, reverse. TSS, transcription start site. P, the probe for
TaqMan-MSP. A total of 36 CGs were numbered from the first to
last CG in the sequences as indicated. Individual CpG methylation
in cell lines (b) and primary ESCC (PT) with their corresponding
normal esophageal tissues (PN) is shown (c). HEK293 human
embryonic kidney cell line was included to compare CpG
methylation between cancer and non-tumorigenic cell lines. CpGs
undetermined were not squared. Black square, methylated CpG;
white square, unmethylated CpG; shaded square, partially
methylated CpG. The criteria to determine methylation in
individual CpG are described in the Supplemental Methods.
When analyzed in the region downstream of the TSS (indicated as
Bi-F3 and Bi-R2) by bisulfite-sequencing, NEFH methylation was
observed in normal tissue samples collected from ESCC patients
and HEK293 cells as well as 12 ESCC cell lines, indicating that
NEFH methylation in the promoter region upstream of the TSS
discriminates normal and tumor tissues. d, Bisulfite-sequencing
results of the NEFH promoter in 12 ESCC cell lines, HEK293
cells, and primary ESCC (PT) together with their corresponding
normal esophageal tissues (PN). Black square, methylation; white
square, no methylation. e, Representative results of NEFH
bisulfite-sequencing in cell lines and tissues. All guanines present
after sequencing that are complementary to methyl cytosines on
the opposite DNA strand. Arrow, methylated CpGs maintained
after bisulfite treatment. f, Promoter methylation of NEFH in
ESCC cell lines was further confirmed by combined bisulfite
restriction analysis (COBRA) after gel-extraction of the PCR
product of bisulfite-treated DNA. Only the PCR products of the
methylated alleles are cleaved by the enzyme BstUI that
recognizes the sequence CGCG, not CUCU. Samples were
loaded on a 10% acrylamide gel, stained with 1X SYBR Green
Gold and visualized under UV light. L, 1 Kb Plus DNA ladder.
Arrows, 100 bp.
Found at: doi:10.1371/journal.pone.0009003.s002 (16.14 MB
TIF)
Figure S2 Establishment of NEFH or control shRNA stable
clones. Two stable clones expressing low levels of NEFH (N12
and N20) and a non-targeting control clone (C2) were established
in KYSE30 cells for further study by selection of GFP-expressing,
puromycin-resistant cells after transfection of shRNA plasmid to
inhibit the endogenous NEFH expression (Material and Meth-
ods). NEFH-knockdown at the mRNA level was confirmed by
RT-PCR (a) and real-time RT-PCR analysis (b), and at the
protein level by fluorescence microscopy and by western blot
analysis (c). The knockdown of NEFH was greater in the N20
than in the N12 clone. d, To con f i r mN E F He x p r e s s i o n ,I H C
analysis was performed in tissue sections of tumor xenografts
dissected from mice. Expressions of b-catenin, PK-M2 and PDH
in tumor xenografts were consistent with those observed in
protein lysates from cell culture as shown in Figure 3. Scale bar,
10 mm.
Found at: doi:10.1371/journal.pone.0009003.s003 (3.60 MB TIF)
Figure S3 Activation of b-catenin-TCF/Lef signaling by
NEFH-knockdown. a, The slight increase of total Akt in
NEFH-deficient cells was due to increased Akt1 and Akt2 in
N12 and N20 cells, respectively. b, Basal expression of phospho-
Akt and b-catenin was examined in ESCC cell lines. Cell lysates
from ESCC cell lines were run in 4-12% polyacrylamide gel and
transferred onto nitrocellulose membrane. Cell lysate from SH-
SY5Y was loaded together to compare NEFH level with those in
ESCC cell lines. Exposure time of the protein membrane on X-
ray film after extensively washing was 10 sec (short) and 1 min
(long). Faint expression of NEFH was detected in TE series by
relatively long exposure (1 min) of the protein membrane reacted
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b-catenin was observed in all 12 ESCC cell lines (data not
s h o w n ) .c ,N E F He x p r e s s i o nw a sundetectable in KYSE140 cells
that harbored NEFH promoter methylation (Fig. 1). The NEFH
promoter was not methylated in HEK293 cells and SH-SY5Y a
neuroblastoma cell line (determined by Bisulfite-sequencing
analysis), and high levels of NEFH were detected in these cell
lines. KYSE140 cells were transfected with pcDNA3.1 (mock) or
NEFH expressing plasmid (pNEFH). Interestingly, phospho-Akt
and b-catenin levels seemed to be inversely correlated with
NEFH expression. Gsk3b expression was positively correlated
with NEFH level in KYSE30 and KYSE140 cells. d, HEK293
cells were transfected with NEFH-siRNA and non-targeting
control, and total cell lysates were extracted for Western blot
analysis. b-actin is a loading control. Increased cell proliferation
was observed in HEK293 cells transfected with siRNA targeting
NEFH (data not shown). Real-time RT-PCR was performed
using cDNA prepared from C2, N12 and N20 (e) or KYSE140
cells (f) 72 hrs after transfection using TaqMan pre-designed
primers and probes as described in Methods. Transcriptional
level of each gene was normalized by the level of b-actin. NEFH
deficiency increased mRNA expression of b-catenin and
downstream target genes (TCF1, cyclin D1, and MMP-7).
Values are expressed as means 6 SD, and experiments were
done in triplicate, and repeated twice. Expression of NEFH was
confirmed by RT-PCR (Box).
Found at: doi:10.1371/journal.pone.0009003.s004 (1.67 MB TIF)
Figure S4 Cellular resistance to oxidative stress by NEFH-
knockdown. a, Cellular resistance to oxidative stress was increased
by down-regulation of NEFH. KYSE30 cells (left) and HEK293
cells (right) were transfected with NEFH- (N) or control-siRNA (C)
and exposed to H2O2 (0 {similar, tilde operator } 400 mM) in
serum-free medium for 2 hrs. Cells were then recovered from
oxidative stress by further incubation in growth medium for 24
(KYSE30, left) or 48 hrs (HEK293, right). KYSE30 cells were
more sensitive to oxidative stress than HEK293 cells, since the
sensitivity of KYSE30 cells to H2O2 treatment was seen in 24 hrs
of recovery whereas that of HEK293 cells was observed in 48 hrs
of recovery. In the presence of NEFH knockdown, an increased
cell survival to H2O2 exposure was seen in both cell types,
indicating cellular resistance to oxidative stress by down-regulation
of NEFH. Data are expressed as % of untreated control. Values
are expressed as means 6 SD, and experiments were repeated
twice in triplicate. b, KYSE140 cells were transiently transfected
with NEFH expressing plasmid or control plasmid (p3.1) and
treated with or without H2O2 (100 mM) in serum-free medium for
2 hrs. After 24 hrs of recovery, cell viability was examined. In the
absence of H2O2 treatment, the viability in cells expressing NEFH
was about 70% of control, whereas in the presence of H2O2
treatment, the decrease of cell viability was further enhanced to
50% of control. These results suggest that NEFH sensitizes cells to
oxidative stress. *, P,0.05 (T-test). c, Valinomycin is a potassium
ionophore that collapses mitochondrial membrane potential, and
loss of mitochondrial membrane potential is observed in the early
stages of apoptosis. HEK293 cells transfected with NEFH- (N) or
control-siRNA (C) were treated with Valinomycin (0 {similar, tilde
operator } 10 nM) for 16 hrs, and cell survival was examined.
Down-regulation of NEFH by siRNA transfection increased cell
survival against Valinomycin-induced apoptosis, indicating that
loss of NEFH in ESCC promotes cellular resistance to oxidative
stress and mitochondrial dysfunction. d, Dym was determined by
flow cytometry after staining C2 and N20 cells with a membrane
potential sensitive dye, JC-1 (upper). Quadrant statistics for the
population of cells that resided at UR and LR (lower). e, The red
(J-aggregates) and green (JC-1 mononer) fluorescence intensities
were analyzed by flow cytometry, and the ratio of red to green
fluorescence was calculated. Values are expressed as means 6 SD,
and experiments were done in triplicate.
Found at: doi:10.1371/journal.pone.0009003.s005 (3.43 MB TIF)
Figure S5 b-catenin knock-down inhibits cell growth. a, Dym
was determined after staining cells with a membrane potential
sensitive dye, JC-1. Fluorescence intensity was acquired by reading
cells in a fluorescence microplate reader. Values are expressed as
means 6 SD, and experiments were done in triplicate. b, Cellular
growth was evaluated by the MTT cell growth assay for 4 days
after transfection of b-catenin siRNA. No significant difference in
cell growth was found in 24 hr, but cell growth was inhibited in
both C2 and N20 cells by the b-catenin knockdown after 3 days of
incubation. Data are expressed as absorbance at 570 nm and
experiments were repeated twice in triplicate.
Found at: doi:10.1371/journal.pone.0009003.s006 (1.46 MB TIF)
Figure S6 Cells with low expression of NEFH are more sensitive
to API-2 or 2-DG. a, Cells were incubated in complete growth
medium (2 mg/ml glucose) in the presence of 2-DG (0 {similar,
tilde operator } 3 mg/ml) or were incubated under glucose-free
condition for 24 hrs, and cell viability was assessed by the MTT
assay. Values are expressed as means 6 SD of absorbance at
570 nm (left), or % of control (no treatment) in each cell line.
Experiments were repeated twice and done in triplicate. *, P,0.05.
b, Cell viability was evaluated 24 hrs after the treatment of
inhibitors. UC, untreated control; LY, LY294002 (10 mM); API-2
(10 mM); QNZ (50 mM). c, Oxygen consumption (left) and ATP
levels (right) were measured after treatment of 2-DG or API-2. d,
Representative results of ROS imaging after 2-DG or API-2
treatment in C2 and N20 cells. e, In 8 hrs, cell viability was not
significantly decreased by 2-DG or API-2 treatment (left, MTT
assay), but inhibition of cell viability was observed at 24 hrs of
treatment (right, coulter counting). f, C2 and N20 cells were treated
with LY294002 (10 mM) and Wortmannin (1 mM) for 2 and 20 hrs,
and western blot analysis was performed. g, C2 cells were pre-
treated with LY294002 and Wortmannin for 1 hr, and EGF
(10 ng/ml) was added. Cells were then further incubated for 2 hrs,
and western blot analysis was performed. Similar results were
observed in cells treated with inhibitors for 16 hrs (data not shown).
Found at: doi:10.1371/journal.pone.0009003.s007 (10.30 MB
TIF)
Table S1
Found at: doi:10.1371/journal.pone.0009003.s008 (0.03 MB
XLS)
Table S2
Found at: doi:10.1371/journal.pone.0009003.s009 (0.05 MB
XLS)
Table S3
Found at: doi:10.1371/journal.pone.0009003.s010 (0.04 MB
XLS)
Table S4
Found at: doi:10.1371/journal.pone.0009003.s011 (0.03 MB
XLS)
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